Sign inJoin waitlistJoin the waitlist

Eric Jonasch

Professor, Genitourinary Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

Beth Israel Deaconess Medical Center
1997–1999
Hematology and Medical Oncology Research Training
Tufts Medical Center
1995–1997
Royal Victoria Hospital
1992–1995
Medical Oncology
1993–1995
UNIV OF MONTREAL, MONTREAL
1988–1992

Research

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy · 2016 · 4,439 citations
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Annals of Oncology · 2021 · 855 citations
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
New England Journal of Medicine · 2021 · First of 16 authors · 594 citations

Nizar Tannir
124 papers
Surena Matin
55 papers
Pheroze Tamboli
46 papers
Jose Karam
35 papers · 2 as a fellow
KS
Kanishka Sircar
32 papers
Pavlos Msaouel
31 papers · 20 as a fellow
Matthew Campbell
28 papers · 2 as a fellow
Toni Choueiri
28 papers
CW
Christopher Wood
25 papers
Amishi Shah
24 papers · 2 as a fellow
RM
Robert Motzer
22 papers
Brian Rini
20 papers

Grants

Biannual von Hippel Lindau Family Alliance Medical Meeting
National Cancer Institute · R13
Contact PI · $8K · University of Tx Md Anderson Can Ctr
2011–2012

Clinical trials

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2029
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2029
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2030
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2025